Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has announcements × KD025 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Bronchiolitis Obliterans Syndrome 1

Interventions

TIC10 compound 3 trastuzumab deruxtecan 2 umbralisib 1 ublituximab 1 duvelisib 1 blinatumomab 1 belumosudil 1 Rituximab 1 KD025 1 Crizotinib 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Sanofi

Phase 2 Terminated

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡